SphK2 Antibody (YA5478)
(Synonyms: Sphingosine kinase 2; SK 2; SPK 2; )
Based on 1 Customer Validation
SphK2 Antibody (YA5478) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SphK2.
-
Host:
Mouse
-
Application:
WB, IHC-P
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS containing 50% glycerol, and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-2000 | 1:50-200 |
Product Details
SphK2 Antibody (YA5478) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SphK2.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Calculated Molecular Weight Predicted band size: 72 kDa
Synthesized peptide derived from human SPHK2
affinity chromatography.
Non-conjugated
Unmodified
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS containing 50% glycerol, and 0.02% sodium azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
SphK2 catalyzes phosphorylation of sphingosine to generate sphingosine-1-phosphate (S1P), a bioactive lipid linked to extracellular, cytosolic, and nuclear signaling[1][2]. Mechanistically, the SPHK2/S1P pathway regulates transcription, telomere maintenance, and mitochondrial respiration, while S1P also signals through S1PR1-5 receptors[1][3]. In disease models, SphK2 appears in studies of cancer, fibrosis, sickle cell disease, renal fibrosis, neuroinflammation, and neoplastic mast-cell growth[3][4][5][6]. Compared with SphK1, SphK2 shows distinct tissue distribution, later embryonic expression, larger protein size, different catalytic properties, and localization to the nucleus, endoplasmic reticulum, and mitochondria[1][2]. This isoform distinction supports selective inhibitor design, because SphK2 remains less understood than SphK1 and lacks sufficiently selective chemical tools in earlier studies[7][8]. For experimental applications, SphK2-selective inhibitors have reduced S1P levels in U937 cells, increased blood or circulating S1P after in vivo administration, and enabled structure-activity studies of potency, selectivity, and target engagement[4][9][10].
-
Subcellular Localization
Cytoplasm; Nucleus; Endoplasmic reticulum; Mitochondrion inner membrane; Lysosome membrane
-
Expression
Tissue_specificity:Mainly expressed in adult kidney, liver, and brain (PubMed:10751414) . Expressed in cerebral cortex and hippocampus (at protein level) (PubMed:29615132) . Isoform 1 is the predominant form expressed in most tissues (PubMed:16103110) -
Isoforms & Post-Translational Modification
Q9NRA0 has 5 isomers: Q9NRA0-1: 69217 Da (predicted); Q9NRA0-2: 65205 Da (predicted); Q9NRA0-3: 65170 Da (predicted); Q9NRA0-4: 62986 Da (predicted); Q9NRA0-5: 80205 Da (predicted).
Phosphorylated by PKD on Ser-419 and Ser-421 upon PMA treatment. Phosphorylation induces export from the nucleus to the cytoplasm (PubMed:17635916). Phosphorylated by MAPK1 and MAPK2 at Ser-387 and Thr-614, phosphorylation is induced by agonists such as EGF and PMA and increases kinase activity (PubMed:17311928);Cleaved by CASP1 in apoptotic cells. The truncated form is released from cells -
Subunit
Interacts with histone H3 (PubMed:19729656). Interacts with HDAC1, HDAC2, MBD2 and SIN3A (PubMed:19729656). Interacts with EEF1A1; the interaction enhances SPHK2 kinase activity (PubMed:18263879).
-
SwissProt ID
-
Synonyms
Sphingosine kinase 2; SK 2; SPK 2;
Documentation
[1]. Diaz Escarcega R, et al. The Functional Role of Sphingosine Kinase 2. Front Mol Biosci. 2021 May 14;8:683767. [Content Brief]
[2]. Liu H, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000 Jun 30;275(26):19513-20. [Content Brief]
[3]. Santos WL, et al. Drugging sphingosine kinases. ACS Chem Biol. 2015 Jan 16;10(1):225-33. [Content Brief]
[4]. Mócsai A, et al. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol. 1999 Jan 15;162(2):1120-6. [Content Brief]
[5]. Bandara G, et al. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. Front Immunol. 2018 Mar 28;9:631. [Content Brief]
[6]. Standoli S, et al. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. [Content Brief]
[7]. Knott K, et al. Effect of alkyl chain length on sphingosine kinase 2 selectivity. Bioorg Med Chem Lett. 2012 Nov 15;22(22):6817-20. [Content Brief]
[8]. Congdon MD, et al. Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors. Bioorg Med Chem Lett. 2015 Nov 1;25(21):4956-4960. [Content Brief]
[9]. Patwardhan NN, et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015 Feb 26;58(4):1879-1899. [Content Brief]
[10]. Pashikanti S, et al. Sphingosine Kinase 2 Inhibitors: Rigid Aliphatic Tail Derivatives Deliver Potent and Selective Analogues. ACS Bio Med Chem Au. 2022 Oct 19;2(5):469-489. [Content Brief]
Powered by Bioz
